Clinical trial · Interventional
Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors
Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well thiotepa works together with radiation therapy in treating young patients with newly diagnosed malignant brain tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| thiotepa | Drug | Thiotepa | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Degree of surgical resection by surgical and radiological assessments
Secondary outcomes (1)
- measure
- Tumor response to chemotherapy by imaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 20 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed diagnosis of 1 of the following high-grade (malignant) astrocytic tumors:
* Anaplastic astrocytoma
* Glioblastoma
* Giant cell glioblastoma
* Gliosarcoma
* Any anatomical site except brain stem
* Newly diagnosed disease
* Has undergone tumor biopsy or surgical resection within the past 2 weeks
* Patients with post-operative residual disease (grade III or IV) are eligible
* Post-operative imaging of tumor within 72 hours of surgery
* Patients with no imageable post-operative disease are not eligible
* No neurological deterioration within 3 days of study treatment
* Increasing requirement for steroids to control symptoms of intracranial pressure is considered evidence of neurological deterioration
PATIENT CHARACTERISTICS:
* Lansky play score 40-100%
* Absolute neutrophil count \> 1,000/mm\^3
* Platelet count \> 100,000/mm\^3
* Creatinine ≥ 1.5 times upper limit of normal
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior chemotherapy or radiotherapyReferences
Publications (0)
Data not yet available